عربي
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D INGELHEIM, Germany -Tuesday 5 April 2022
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches expected until 2025 (BUSINESS WIRE)--...
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection...
-Saturday 6 November 2021 
- In a new sub-analysis of the landmark EMPEROR-Preserved® Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline1 - Empagliflozin consistently improved outcomes across the full...
Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing... -Friday 29 October 2021
The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial (BUSINESS WIRE)-- Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular...
Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major... -Wednesday 27 October 2021
(BUSINESS WIRE) -- Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive...
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in... -Thursday 16 September 2021
Combination of leading SOS1::pan-KRAS inhibitor with the first US FDA approved KRASG12C inhibitor has the potential to demonstrate additional therapeutic benefit for people living with KRAS G12C mutated cancers The new clinical partnership adds to Boehringer Ingelheim’s comprehensive...
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
-Thursday 9 September 2021
(BUSINESS WIRE) -- Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s...
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction...
-Thursday 9 September 2021
(BUSINESS WIRE)-- The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for empagliflozin as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY)...
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH -Wednesday 2 June 2021
FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH. Boehringer Ingelheim’s focus on the development of next generation NASH treatments builds on its strong...
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart...
-Friday 21 May 2021
(BUSINESS WIRE) -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF),...
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the... -Monday 10 May 2021
(BUSINESS WIRE) -- Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world. Post-doctoral...
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in... -Wednesday 14 April 2021
(BUSINESS WIRE) -- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2...
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT... -Tuesday 16 March 2021
Through the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia. The new collaboration further expands...
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared... -Tuesday 12 January 2021
(BUSINESS WIRE)-- Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration...
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase -Friday 18 December 2020
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus...
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline... -Thursday 10 December 2020
(BUSINESS WIRE)-- Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune...
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology... -Wednesday 9 December 2020
(BUSINESS WIRE)-- Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology...
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer -Monday 7 December 2020
- New collaboration strengthens Boehringer Ingelheim’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancers - Proxygen’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis...
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and...
-Wednesday 18 November 2020
- In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established...
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 -Thursday 5 November 2020
(BUSINESS WIRE)-- Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published online as part of ACR Convergence...
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness... -Wednesday 28 October 2020
(BUSINESS WIRE) -- Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute...